A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China (ADMIRE)

Bristol-Myers Squibb (BMS)

Status: Enrolling

Conditions: Plaque Psoriasis

Treatments: Drug: Deucravacitinib

Study type: Observational

Funder types: Industry

Identifiers

NCT06512337

IM011-1180

Details and patient eligibility

About

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant aged 18 years or older
• Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
• Participant newly initiated deucravacitinib according to the label
• Provided written informed consent to participate in the study

Exclusion criteria

• Participating in or planning to participate in an interventional clinical trial
• Concomitant use of other systemic treatments for psoriasis at baseline
• Prior treatment of deucravacitinib

Trial design

150 participants in 1 patient group

Participants treated with deucravacitinib

Description:

Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label

Treatment:

Drug: Deucravacitinib